Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CCR4 | P51679 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755706 | 1.00 | RORC (0.33) | RORCTSHRCCR4ALDH1A1KCNJ5 | |
| SCHEMBL9275751 | 0.79 | AGXT (0.34) | TSHRHTTRECQL | |
| SCHEMBL29755825 | 0.79 | AGXT (0.34) | TSHRHTTRECQL | |
| SCHEMBL22564749 | 0.79 | CCR1 (0.35) | RORCTSHRCCR4KCNJ5KCNJ3 | |
| SCHEMBL27916480 | 0.78 | AGXT (0.41) | RORCCCR4ALDH1A1KCNJ5KCNJ3 | |
| SCHEMBL22224634 | 0.76 | HTT (0.37) | RORCHTTRECQL | |
| SCHEMBL23723621 | 0.76 | KCNJ5 (0.33) | RORCCCR4KCNJ5KCNJ3AXL | |
| SCHEMBL22570334 | 0.73 | CD274 (0.33) | RORCCCR4 | |
| SCHEMBL22340093 | 0.73 | RORC (0.34) | RORCCCR4AXLPRKCI | |
| SCHEMBL22570339 | 0.73 | RORC (0.34) | RORCCCR4KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | NOVIRA THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| EP-4051672-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650988-A | Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases | 詹森生物科技公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2021084500-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | DHODH, NQO2, DPYD | RORC 939/4885TSHR 2863/4885CCR4 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.